Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc Ord (OP: AZNCF )

147.70 +1.62 (+1.11%)
Streaming Delayed Price Updated: 12:17 PM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc Ord

< Previous 1 2 3 4 5 6 7 8 Next >
AstraZeneca - Amgen's Tezspire Biologic Scores FDA Approval For Severe Asthma
The FDA has approved AstraZeneca plc (NASDAQ: AZN) / Amgen Inc's (NASDAQ: AMGN) Tezspire (tezepelumab-ekko) as add-on maintenance treatment of adult... 
Via Benzinga
Johnson & Johnson's, Sputnik, Sinopharm COVID-19 Vaccines Show Weakness Against Omicron Variant: Study
COVID-19 vaccines from China's state-owned Sinopharm and Johnson & Johnson (NYSE: JNJ) and Russia developed Sputnik were found to produce little or no... 
Via Benzinga
AstraZeneca's COVID-19 Antibody Effective Against Omicron Variant
New preclinical data released by AstraZeneca Plc (NASDAQ: AZN) shows that its long-acting antibody Evusheld (tixagevimab co-packaged with cilgavimab) works against... 
Via Benzinga
Sanofi, Glaxo's COVID-19 Vaccine Candidate Works As Booster, But Data Readout Pushed Back
Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc (NYSE: GSK) expect data from late-stage trials of its COVID-19 booster dose in Q1 2022, instead of this year.... 
Via Benzinga
Samsung Biologics, AstraZeneca Expand Collaboration To Include COVID-19, Cancer Therapy
Samsung Biologics Co Ltd said it would continue its partnership with AstraZeneca Plc (NASDAQ: AZN) on manufacturing biopharmaceuticals. According to Samsung, the production... 
Via Benzinga
AstraZeneca's Dapagliflozin No Longer Authorized For Type 1 Diabetes In UK
On 25 October 2021, the marketing authorization holder for dapagliflozin withdrew the indication for type 1 diabetes across Europe and the U.K. The SGLT2 inhibitor... 
Via Benzinga
Innate Pharma Says Chemo-Free Monalizumab Triplet Therapy Shows Preliminary Anti-Cancer Activity
Innate Pharma SA's (NASDAQ: IPHA) data from the Phase 2 expansion cohort (cohort 3) evaluating the monalizumab triplet combination shows preliminary activity and an... 
Via Benzinga
AstraZeneca's COVID-19 Therapy Wins FDA Approval As First Antibody To Prevent Infection In Immunocompromised
The FDA authorized the use of AstraZeneca Plc's (NASDAQ: AZN)antibody cocktail to prevent COVID-19 infections in individuals with weak immune systems or a... 
Via Benzinga
Exposures COVID-19 Product Safety
Mix & Match Pfizer, AstraZeneca COVID-19 Vaccine With Moderna Shows Improved Immune Response
A British study evaluating mixing COVID-19 vaccines showed a better immune response in people after the first dose of AstraZeneca Plc (NASDAQ: AZN) or ... 
Via Benzinga
Exposures COVID-19
Ionis, AstraZeneca Ink Licensing Pact For Eplontersen In Protein Misfolding Disorder
Ionis Pharmaceuticals Inc (NASDAQ: IONS) has entered into a strategic collaboration agreement with AstraZeneca Plc (NASDAQ: AZN) to develop and... 
Via Benzinga
Valneva's COVID-19 Shot Fails As Booster In Pfizer/BioNTech Vaccinated Population
Valneva SE (NASDAQ: VALN) has responded to data published from the U.K COV-Boost COVID-19 vaccine trial that investigated the reactogenicity and immunogenicity of... 
Via Benzinga
Exposures COVID-19
AstraZeneca Blocks SOBI's $8B Buyout, Advent Withdraws The Bid - Report
AstraZeneca Plc (NASDAQ: AZN) blocked an $8 billion takeover of Swedish Orphan Biovitrum AB (OTC: BIOVF) by withholding its 8% stake in SOBI from a buyout offer by... 
Via Benzinga
Possible New Links Identified With AstraZeneca COVID-19 Shot, Blood Clots
Scientists have identified a possible reason the AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine may cause blood clots after the use of the shot was limited to... 
Via Benzinga
Exposures COVID-19
AstraZeneca-Merck's Lynparza Under FDA Priority Review For Breast Cancer Setting
The FDA has granted priority review for AstraZeneca Plc's (NASDAQ: AZN) supplemental marketing application for Lynparza (olaparib) for breast cancer.... 
Via Benzinga
Exposures Product Safety
AstraZeneca's COVID-19 Vaccine Turns Profitable In Q3; Reaffirms FY21 Guidance
AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine made a small contribution to earnings in Q3. It expects the shot to move to "modest profitability" on new... 
Via Benzinga
Exposures COVID-19
AstraZeneca Plans To Set Up Separate Division For Vaccines & Antibody Therapies - Report
AstraZeneca plc (NASDAQ: AZN) is reportedly creating a separate division for vaccines and antibody therapies, primarily to focus on its COVID-19 shot and... 
Via Benzinga
Exposures COVID-19
AstraZeneca's Medimmune Terminates DNA Cancer Vaccine Program With Inovio
MedImmune Limited, a unit of AstraZeneca Plc (NASDAQ: AZN), has notified Inovio Pharmaceuticals Inc (NASDAQ: INO) to terminate the DNA cancer vaccine... 
Via Benzinga
AstraZeneca To Offload Some Drug Rights To Covis Pharma For $270M
AstraZeneca Plc (NASDAQ: AZN) will transfer global rights for respiratory medicines Eklira and Duaklir to Covis Pharma Group for $270 million. Covis will also... 
Via Benzinga
AstraZeneca's Imfinzi/Chemo Combo Strikes First Immunotherapy Wins In Bile Duct Cancer Trial
AstraZeneca Plc (NASDAQ: AZN) revealed topline results from the Phase 3 TOPAZ-1 study. Related: AstraZeneca Touts Longest Survival Update In Lung Cancer... 
Via Benzinga
AstraZeneca Pulls Plug On MCL-1 Cancer Drug Trial
AstraZeneca Plc (NASDAQ: AZN) has paused an active Phase 1 trial of AZD5991, a direct inhibitor of MCL-1, citing a potential safety issue. Two years ago, the FDA hit ... 
Via Benzinga
Exposures Product Safety
AstraZeneca's COVID-19 Therapy Hits Goal In Phase 3 Trial
AstraZeneca Plc (NASDAQ: AZN) released top-line data from the TACKLE Phase 3 trial in which its experimental COVID-19 drug has helped cut the risk of severe disease... 
Via Benzinga
Exposures COVID-19
AstraZeneca Seeks Emergency Use Nod For COVID-19 Drug To Prevent Infection
AstraZeneca Plc (NASDAQ: AZN) has filed for an FDA Emergency Use Authorization (EUA) of AZD7442, its long-acting antibody (LAAB) combination, for prophylaxis of... 
Via Benzinga
Exposures COVID-19 Product Safety
EMA's Risk Assessment Committee Finds Link Of Rare Cases Between JNJ COVID-19 Shot, Blood Clots
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) has concluded a possible link to rare cases of venous thromboembolism (VTE) with... 
Via Benzinga
Exposures COVID-19
AstraZeneca COVID-19 Jab Shows 74% Efficacy In US Trial
Reuters reported that large U.S. trial results of AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine demonstrated 74% efficacy at preventing symptomatic disease... 
Via Benzinga
Exposures COVID-19
Adagio's COVID-19 Candidate Shows Prolonged Half-Life, Neutralization At Six Months
Adagio Therapeutics Inc (NASDAQ: ADGI) has announced new data from its COVID-19 antibody program. Related Link: Adagio Therapeutics To Expand Late-Stage... 
Via Benzinga
Exposures COVID-19
AstraZeneca Buys Fortress-Biotech Founded Caelum For $500M
AstraZeneca Plc (NASDAQ: AZN) will take complete control of Caelum Biosciences in a deal worth up to $500 million, sharpening its focus on rare-disease... 
Via Benzinga
AstraZeneca's Saphnelo For Lupus Treatment Approved In Japan
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved AstraZeneca plc’s (NASDAQ: AZN) Saphnelo (anifrolumab) for systemic lupus... 
Via Benzinga
AstraZeneca, Sputnik Light COVID-19 Vaccine Mix Shows Strong Antibody Growth: Reuters
A small-scale study of AstraZeneca Plc (NASDAQ: AZN) COVID-19 combined with Sputnik Light vaccines has shown robust antibody growth in most of the study's... 
Via Benzinga
Exposures COVID-19
AstraZeneca - Merck's Lynparza Delays Disease Progression In Prostate Cancer Patients
AstraZeneca Plc (NASDAQ: AZN) has reported high-level results from the PROpel Phase 3 trial of Lynparza (olaparib) in metastatic castration-resistant prostate... 
Via Benzinga
AstraZeneca Invests In Imperial College's Self-Amplifying RNA Tech
AstraZeneca Plc (NASDAQ: AZN) struck a deal with a startup for a self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London. Under the... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.